{"id":849627,"date":"2025-05-09T16:11:56","date_gmt":"2025-05-09T20:11:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"},"modified":"2025-05-09T16:11:56","modified_gmt":"2025-05-09T20:11:56","slug":"exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","title":{"rendered":"Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CARLSBAD, Calif., May  09, 2025  (GLOBE NEWSWIRE) &#8212; Exagen Inc.\u00a0(Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025.<\/p>\n<p>All of the shares in the public offering, including the full exercise of the underwriter\u2019s option, were sold by Exagen, with gross proceeds to Exagen of approximately $20.2 million, before deducting underwriting discounts and commissions and offering expenses.<\/p>\n<p>Canaccord Genuity acted as sole bookrunner for the offering.<\/p>\n<p>The public offering was made pursuant to a shelf registration statement on Form S-3 (including a base prospectus) that was previously filed with the Securities and Exchange Commission (the \u201cSEC\u201d) and declared effective by the SEC on November 29, 2023. A final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC\u2019s website located at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cW3_CbJW5zmqyv7-AosJ3umTlunLexfZFzpG26yF56R8jKGw_pUsldprdq0IGcrPbSv77uyj2j2XoRdBT-Zw_bUKgjR_bxHhlywBMGbkuTI=\" rel=\"nofollow\" target=\"_blank\">http:\/\/www.sec.gov<\/a>, and may be obtained from Canaccord\u00a0Genuity LLC, Attention: Syndication Department, 1 Post Office Square, Suite 3000, Boston, MA 02109, or by email at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p19yo-23_rjuwtLrRr1BRlnJDFduwxYtw26VyM7hjkOyejAlYH0mEJNBt0naKky8M6o8_HliqGq4rL-_Ndp-j0FSEnhUDomX2i5ice56T6w=\" rel=\"nofollow\" target=\"_blank\">prospectus@cgf.com<\/a>.<\/p>\n<p>This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.<\/p>\n<p>\n        <strong>About\u00a0Exagen<\/strong>\n      <\/p>\n<p>Exagen Inc.\u00a0(Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in\u00a0San Diego County, California, Exagen\u2019s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The Company\u2019s flagship product, AVISE<sup>\u00ae<\/sup>\u00a0CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sj\u00f6gren\u2019s syndrome earlier and with greater accuracy. Exagen\u2019s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE<sup>\u00ae<\/sup>-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care,\u00a0Exagen\u00a0is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, please visit\u00a0Exagen.com\u00a0or follow @ExagenInc on X.<\/p>\n<p>\n        <strong>Contact<\/strong>\n      <\/p>\n<p>Ryan Douglas<br \/>Exagen Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oMhhCbwB1AptK8_KOABxHGWQ8iullQ1CjI_gboctW-0ZrdbRQ16jBJB4HAbC2Wacedw_Ismrm-Xav2jCFmnVDN5GFc-yQ8oVkUSX6NkguEply4VXarXrDRb7AAqasWn-6VjuWpbUQldzgKi0CN3F74DGGHs07goGR8Y5KC5zKuF0Ep58VH1hlkCebqpwmZzNlQqNwZSGCOYHS6A1DvX6brn8E0vvbVPYF2Q2PTZZh5o=\" rel=\"nofollow\" target=\"_blank\">ir@exagen.com<\/a><br \/>760.560.1525<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0ODU5NyM2OTMyOTIzIzIwMTA5NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzM0ZDgwYzAtMWNkNi00MzI3LWE4NzAtZjE0YmYzMzVhZDNkLTEwMjI1NDUtMjAyNS0wNS0wOS1lbg==\/tiny\/Exagen-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) &#8212; Exagen Inc.\u00a0(Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025. All of the shares in the public offering, including the full exercise of the underwriter\u2019s option, were sold by Exagen, with gross proceeds to Exagen of approximately $20.2 million, before deducting underwriting discounts and commissions and offering expenses. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-849627","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) &#8212; Exagen Inc.\u00a0(Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025. All of the shares in the public offering, including the full exercise of the underwriter\u2019s option, were sold by Exagen, with gross proceeds to Exagen of approximately $20.2 million, before deducting underwriting discounts and commissions and offering expenses. &hellip; Continue reading &quot;Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-09T20:11:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0ODU5NyM2OTMyOTIzIzIwMTA5NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares\",\"datePublished\":\"2025-05-09T20:11:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"},\"wordCount\":454,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0ODU5NyM2OTMyOTIzIzIwMTA5NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\",\"name\":\"Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0ODU5NyM2OTMyOTIzIzIwMTA5NzI=\",\"datePublished\":\"2025-05-09T20:11:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0ODU5NyM2OTMyOTIzIzIwMTA5NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0ODU5NyM2OTMyOTIzIzIwMTA5NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","og_locale":"en_US","og_type":"article","og_title":"Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk","og_description":"CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) &#8212; Exagen Inc.\u00a0(Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025. All of the shares in the public offering, including the full exercise of the underwriter\u2019s option, were sold by Exagen, with gross proceeds to Exagen of approximately $20.2 million, before deducting underwriting discounts and commissions and offering expenses. &hellip; Continue reading \"Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-09T20:11:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0ODU5NyM2OTMyOTIzIzIwMTA5NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares","datePublished":"2025-05-09T20:11:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"},"wordCount":454,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0ODU5NyM2OTMyOTIzIzIwMTA5NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/","name":"Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0ODU5NyM2OTMyOTIzIzIwMTA5NzI=","datePublished":"2025-05-09T20:11:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0ODU5NyM2OTMyOTIzIzIwMTA5NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0ODU5NyM2OTMyOTIzIzIwMTA5NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-closing-of-20-2-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/849627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=849627"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/849627\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=849627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=849627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=849627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}